AVENTIS PHARMA LIMITED
Company Information
- Company Number
- 01535640
- Registered Address
- 410 Thames Valley Park Drive, Reading, Berkshire, England, RG6 1PT
- Status
- Active
- Employee Count
- 693.0
- Turnover
- 417800000.0
- EBITDA
- 1160000.0
Additional Details
- Website
- https://sanofi.co.uk
- Company Type
- Private limited Company
- Incorporated On
- 18 December 1980
- Nature of Business
- 46460 - Wholesale of pharmaceutical goods
- Industries
- Life Sciences And Medical Technology
- Region
- South East
Company Location
Loading map...
Financial Metrics
Time to Pay
Payment Timeline
Payment Features
Payment Time Trends
Payment Distribution Trends
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 30 Jun 2023 - 30 Dec 2023 | 31 Jan 2024 | 75 | 14% | 18% | 68% | 66% |
| 31 Dec 2022 - 29 Jun 2023 | 31 Jul 2023 | 87 | 12% | 16% | 72% | 46% |
| 30 Jun 2022 - 30 Dec 2022 | 30 Jan 2023 | 69 | 19% | 21% | 60% | 40% |
| 31 Dec 2021 - 29 Jun 2022 | 29 Jul 2022 | 60 | 23% | 32% | 45% | 33% |
| 30 Jun 2021 - 30 Dec 2021 | 31 Jan 2022 | |||||
| 30 Jun 2021 - 30 Dec 2021 | 31 Jan 2022 | 64 | 19% | 45% | 36% | 26% |
| 31 Dec 2020 - 29 Jun 2021 | 22 Jul 2021 | 52 | 24% | 54% | 22% | 29% |
| 30 Jun 2020 - 30 Dec 2020 | 18 Jan 2021 | 66 | 15% | 43% | 42% | 30% |
| 31 Dec 2019 - 29 Jun 2020 | 14 Jul 2020 | 54 | 21% | 52% | 27% | 36% |
| 30 Jun 2019 - 30 Dec 2019 | 16 Jan 2020 | 50 | 24% | 55% | 21% | 29% |
| 31 Dec 2018 - 29 Jun 2019 | 25 Jul 2019 | 48 | 27% | 58% | 15% | 29% |
| 30 Jun 2018 - 30 Dec 2018 | 24 Jan 2019 | 45 | 38% | 50% | 12% | 29% |
| 31 Dec 2017 - 29 Jun 2018 | 18 Jul 2018 | 46 | 39% | 44% | 17% | 34% |
Company Summary
AVENTIS PHARMA LIMITED is a global pharmaceutical company that focuses on developing and manufacturing innovative medicines and healthcare solutions
The company was founded in 1999 and is headquartered in Paris, France
AVENTIS PHARMA LIMITED is a subsidiary of Sanofi, a multinational pharmaceutical company
The company's sustainability program is integrated into its business strategy, with a focus on environmental, social, and economic responsibility
AVENTIS PHARMA LIMITED is committed to reducing its carbon footprint and implementing sustainable practices in its operations
It also has a strong focus on promoting diversity and inclusion within its workforce
AVENTIS PHARMA LIMITED offers a wide range of products and services in various therapeutic areas, including cardiovascular, diabetes, oncology, and rare diseases
Its portfolio includes both prescription and over-the-counter medicines, as well as vaccines and consumer healthcare products
The key people at AVENTIS PHARMA LIMITED include its CEO, Olivier Brandicourt, and its Chairman of the Board of Directors, Serge Weinberg
The company has a team of over 100,000 employees worldwide who work towards its mission of improving healthcare and making a positive impact on people's lives
For more information on AVENTIS PHARMA LIMITED, including its products and services, investors, and sustainability efforts, please visit their website at www.aventispharma.com
The company's registered office address is 174 Avenue de France, 75013 Paris, France
Company Review
Trend Analysis
There is a general trend of AVENTIS PHARMA LIMITED taking longer to pay invoices to suppliers over the years. The average time to pay has steadily increased from 46 days in 2017 to 75 days in 2023. This is accompanied by an increase in the percentage of invoices paid later than 60 days, which has risen from 17% in 2017 to 72% in 2023.
Volatility Analysis
There is a high level of volatility in the percentage of invoices paid later than 60 days, with fluctuations ranging from 12% in 2018 to 72% in 2023. This indicates that AVENTIS PHARMA LIMITED does not have a consistent payment pattern and may struggle with timely payments.
Summary Analysis
Looking at the past three periods (2020-2023), there has been an increase in the average time to pay, from 54 days in 2020 to 75 days in 2023. This is a significant increase of 21 days or 38.9%. There has also been a decrease in the percentage of invoices paid within 30 days, from 24% in 2020 to 12% in 2023. On the other hand, there has been an increase in the percentage of invoices paid later than 60 days, from 27% in 2020 to 72% in 2023. This indicates a concerning trend of delayed payments. The shortest (or only) standard payment period for AVENTIS PHARMA LIMITED has remained at 0 days throughout all the periods, indicating that they do not have a standard payment period in place.
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
Standard payment terms are 90 days from the date of receipt of a valid and correct invoice.
Were there any changes to the standard payment terms in the reporting period?
No
Any other information about payment terms
N/A
Maximum contractual payment period agreed
90
Dispute Resolution Process
In the first instance disputes will be received by our Purchase to Pay contact centre at the defined email address or telephone number printed on every Purchase Order. Queries will then be forwarded to the requester of the services/goods for information and evaluation. Failure to meet resolution will be escalated to the Head of Purchase to Pay and include the specific Buyer for the service/goods that is responsible for the vendor relationship.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
✅
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
✅
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
